ALB and Miyoshi myopathy: Patients in the ≥75 group had a lower incidence of some adverse MM risk features compared to the <75 group, including HRCA (44.6% vs. 57.9%, p = 0.03), ultra high-risk (≥2 HRCA) MM (12% vs. 24%, p = 0.02), EMD (22% vs. 40%, p = 0.02), hemoglobin <8 g/dL (10% vs. 21%, p = 0.02) and albumin <3 g/dL (6% vs. 19%, p = 0.04) at the time of starting Tec.